Sanofi and Regeneron’s Dupixent Approved in the US as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria

FDA Approves Dupixent for Young Children with Uncontrolled Chronic Spontaneous Urticaria

The US FDA has approved Dupixent (dupilumab), co-developed by Sanofi and Regeneron, as the first biologic medicine for children aged two to 11 years with uncontrolled chronic spontaneous urticaria (CSU). This expands its previous approval for adults and adolescents. The approval is primarily based on data from the LIBERTY-CUPID clinical study program, which includes extrapolation of efficacy and safety from two Phase 3 studies (Study A and Study C) in older patients, complemented by pharmacokinetic data from the single-arm CUPIDKids Phase 3 study in the younger pediatric population. Dupixent significantly reduced itch severity and urticaria activity compared to placebo in adults and adolescents, with a safety profile consistent with its known profile in other dermatological indications.

• Dupixent has received US FDA approval as the first biologic treatment for children aged two to 11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. This addresses a significant unmet medical need for over 14,000 young children in the US suffering from this debilitating chronic inflammatory skin disease, offering a new targeted therapeutic option where limited alternatives existed.
• The approval is primarily supported by the LIBERTY-CUPID clinical study program. This program leveraged efficacy and safety data extrapolated from two Phase 3 studies (Study A and Study C, NCT04180488) conducted in adults and adolescents (aged 12 years and older) with CSU. These findings were further substantiated by pharmacokinetic data obtained from the single-arm CUPIDKids Phase 3 study (NCT05526521), specifically designed for children aged two to 11 years with CSU.
• In Study A and Study C, Dupixent significantly reduced itch severity and urticaria activity (a composite of itch and hives) compared to placebo at Week 24 in adults and adolescents. It also increased the likelihood of achieving well-controlled disease or complete response. The safety results across all four CSU studies, including CUPIDKids, were generally consistent with Dupixent's established safety profile in its approved dermatological indications, with injection site reactions being the most common adverse event.

Addressing the Significant Unmet Need in Pediatric CSU

Chronic spontaneous urticaria continues to present significant treatment challenges, with multiple patient populations experiencing inadequate symptom control despite current therapies. Recent literature highlights persistent gaps in treatment efficacy and identifies specific subgroups requiring targeted therapeutic approaches.

• Antihistamine-refractory patients represent a major unmet need, with less than 10% achieving complete control on second-generation H1-antihistamines and up to 40% showing no response to high-dose (4-fold) antihistamine therapy

• Omalizumab non-responders and incomplete responders constitute approximately 70% of antihistamine-refractory patients who fail to reach complete control with omalizumab, with only 45% achieving complete hive resolution

• Pediatric and adolescent populations face critical treatment gaps, as pediatric CSU prevalence matches adult rates yet approved treatments remain limited, with guidelines often based on adult studies rather than pediatric-specific evidence

• Patients with psychiatric comorbidities require integrated care approaches, as conditions like generalized anxiety disorder exacerbate CSU through neuro-immuno-cutaneous mechanisms, highlighting the need for mental health interventions alongside conventional therapy

• Autoimmune CSU patients with mast cell-activating immunoglobulin G autoantibodies demonstrate poor or delayed response to omalizumab, necessitating alternative therapeutic strategies

• Treatment adherence challenges affect patient outcomes significantly, with barriers including inconvenience of biologic administration, forgetfulness, healthcare provider dissatisfaction, and logistical access issues requiring streamlined treatment approaches

• Patients requiring long-term remission face unmet needs as current treatments primarily provide symptom control rather than disease modification, with 50% of patients who discontinue omalizumab experiencing relapse

• Atopic CSU subgroups demonstrate differential treatment responses, with comprehensive atopy evaluation needed for therapeutic stratification and personalized treatment approaches based on extrinsic versus intrinsic atopy patterns

Unpacking the LIBERTY-CUPID Program for Pediatric CSU

The LIBERTY-CUPID program represents a comprehensive clinical development approach for pediatric chronic spontaneous urticaria (CSU), incorporating multiple therapeutic modalities and rigorous endpoint assessment strategies. Key trials within this program have employed diverse study designs ranging from randomized controlled trials to real-world observational studies, with consistent focus on validated efficacy measures.

Dupixent's Established Safety and Expanding Role in Type 2 Inflammation

Published safety and tolerability data demonstrate that dupilumab maintains a consistently favorable safety profile across its approved indications. A comprehensive meta-analysis of 32 randomized trials examining 113 types of serious adverse events found that dupilumab was not significantly associated with increased incidence of 112 categories of SAEs, including various infectious diseases. Notably, dupilumab use was significantly associated with lower incidence of atopic dermatitis as a serious adverse event. The favorable safety profile has led to no routine laboratory monitoring being recommended for patients receiving dupilumab therapy.

The most commonly reported adverse events across clinical trials include ocular involvement, nasopharyngitis, and injection site reactions. Real-world data reveals additional adverse events beyond those observed in clinical trials, with conjunctivitis appearing as a dupilumab-specific side effect in atopic dermatitis patients (reported in up to 34% of patients in real-world studies). Chinese real-world data from 138 moderate-to-severe atopic dermatitis patients showed adverse events in 34.1% of patients over 16 weeks, with facial erythema (13%) and ocular symptoms (10.9%) being most frequent. The pathogenesis of adverse events appears to involve Th1/Th2 and Th2/Th17 immune-response imbalances, with heterogeneity and variable onset times warranting thorough patient monitoring.

Analysis of anti-drug antibody development shows treatment-emergent ADAs in up to 8.6% of adult patients, with ≤3.7% having persistent responses and <1% developing high titers. High-titer ADAs were most associated with reduced dupilumab concentrations and loss of efficacy, though efficacy generally remained similar between ADA-positive and negative patients. In specialized indications like prurigo nodularis, dupilumab demonstrated manageable safety profiles with predominantly mild to moderate adverse events and low rates of serious adverse events. Comparative data with other biologics shows dupilumab has higher incidence of conjunctivitis and injection-site reactions compared to tralokinumab, while maintaining comparable serious adverse event rates across Type 2 inflammatory conditions.

Dupixent's New Frontier: Treating Youngest CSU Patients

The recent FDA approval of Dupixent for children aged two to 11 years with uncontrolled chronic spontaneous urticaria (CSU) marks a pivotal moment for pediatric dermatology and immunology. For families grappling with the relentless itch and debilitating hives of CSU in young children, this represents the first biologic treatment option, filling a significant therapeutic void where conventional antihistamines often fall short and other advanced therapies are not yet approved for this specific age group. Dupixent's mechanism, targeting the IL-4Rα subunit to inhibit the type 2 inflammatory pathway, is well-established across a spectrum of allergic diseases, including atopic dermatitis and asthma, where it has demonstrated consistent efficacy and a favorable safety profile.

This expansion into pediatric CSU not only broadens Dupixent's already impressive label but also strategically positions it as a foundational therapy in type 2 inflammation. The regulatory pathway, which involved extrapolating robust data from adult and adolescent studies alongside specific pharmacokinetic data in younger children, highlights an efficient approach to bringing much-needed treatments to rare pediatric conditions. However, the evolving landscape of chronic urticaria presents future considerations. While Dupixent now holds a first-mover advantage in this specific pediatric segment, the broader CSU market is becoming increasingly competitive with established biologics like omalizumab and emerging oral therapies such as remibrutinib, which is already being directly compared to dupilumab in clinical trials.

Looking ahead, continued monitoring of Dupilumab's long-term safety and effectiveness in this very young population will be crucial. While its safety profile has been consistent across indications, real-world data on common adverse events like conjunctivitis and injection site reactions will inform patient and caregiver adherence. Furthermore, while Dupilumab has shown clear benefits in reducing itch and hives, its impact on angioedema and overall quality of life in CSU patients remains an area where more definitive data would strengthen its value proposition. As the understanding of CSU subtypes grows, the future of treatment will likely involve a more tailored approach, and Dupixent's expanded approval ensures it remains a central player in this evolving therapeutic paradigm.